Drug
Regorafenib
Regorafenib: highest development phase Phase 2, developed by MacroGenics, Roche. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- MacroGenics, Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Regorafenib (CT) NCT07071961 | Phase 2 | Colorectal Cancer |
| Regorafenib NCT07223567 | Phase 2 | Rectal Cancer |
| Regorafenib NCT03555149 | Phase 1/2 | Colorectal Cancer |
Latest
No recent events.
Follow Regorafenib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.